Company profile: Varian
1.1 - Company Overview
Company description
- Provider of medical devices and software for treating cancer and other conditions via radiotherapy, radiosurgery, proton therapy, and brachytherapy. Offers informatics software; products such as Ethos Adaptive Radiotherapy System, IntelliBlate Microwave Ablation System, Laguna Thrombectomy System, and Varian Marketplace, plus Advanced Oncology Solutions providing clinical and professional support and workflow solutions.
Products and services
- Ethos Adaptive Radiotherapy System: Clinical-grade radiotherapy system that architects personalized treatment by adapting to patient anatomy and tumor size changes during the treatment process for precise, individualized cancer care
- Advanced Oncology Solutions (AOS): Workflow-centric service that delivers clinical and professional support to optimize oncology technology adoption, including digital oncology tools and workflow systems for comprehensive cancer clinics
- Varian Marketplace: Modular digital platform that supplies Varian software extensions and brachytherapy applicators, allowing third-party developers to share applications with Varian customers
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Varian
Onco-NX
HQ: United Kingdom
Website
- Description: Provider of drug discovery research dedicated to identifying new promising anticancer agents as a University of Salford spin-out company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Onco-NX company profile →
Amal Therapeutics
HQ: Switzerland
Website
- Description: Provider of proprietary oncology immunisation technology and therapeutic cancer vaccines, built on its KISIMA platform that delivers multiple antigens in a single vaccine. Offerings include ATP128, a clinical-stage therapeutic vaccine targeting metastatic colorectal cancer, and collaboration opportunities in immuno-oncology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Amal Therapeutics company profile →
Acrivon Therapeutics
HQ: United States
Website
- Description: Provider of precision oncology therapeutics and companion diagnostics, leveraging the AP3 platform to develop drugs and OncoSignature tests that match therapies to tumor-driving mechanisms. Pipeline includes ACR-368, a phase 2 DNA damage response kinase inhibitor for solid cancers, and ACR-2316, a preclinical selective dual WEE1/PKMYT1 inhibitor.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Acrivon Therapeutics company profile →
Miroculus
HQ: United States
Website
- Description: Provider of hands-off sample-to-answer solutions for molecular testing, delivering assay flexibility and automation via an affordable digital microfluidics platform that enables seamless workflow integration from novel molecular protocols to data analytics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Miroculus company profile →
Attovia Therapeutics
HQ: United States
Website
- Description: Provider of a biologics platform and pipeline of biotherapeutics for immune-mediated diseases, featuring ATTOBODY to generate binders and biparatopic biologics as alternatives to IgG-based medicines; programs include ATTO-1310 (IL31), ATTO-002 (IL31 x IL13), ATTO-004 (novel GPCR), and ATTO-005 (IBD).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Attovia Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Varian
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Varian
2.2 - Growth funds investing in similar companies to Varian
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Varian
4.2 - Public trading comparable groups for Varian
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →